

F. CHARBONNEAU¹, Y. BRASLERET¹, M.A. ZILAVEC¹, C. NAINÉ¹, J. GRIMAUX¹, G. SVRCEK¹

¹Soissons Hospital Center, Pharmacy Unit, Soissons, France

Ms Flora Charbonneau: flora.charbonneau@yahoo.fr

ATC code: L01 - Cytostatics

Background

For several years, healthcare facilities noted the increase of out of supply of medicine including the oncology's field.

Objective

Establish a picture of chemotherapy injectable medicine out of supply and determine the impact on the patients.


Materials & Methods

- Retrospective study during 9 months [from January to September 2019].
- Out of supply are indicated on a frequently updated internal Excel® data base.
- CHIMIO® and EASILY® softwares were used to seek patients affected by chemotherapy injectable medicine ruptures and patient's data.

Results

- 3 chemotherapeutic pharmaceutical specialities identified: Bleomycin, Mitomycin AMETYCINE® and Docetaxel TAXOTERE®.
- 7 patients out of 285 treated with injectable chemotherapy in our healthcare facility were impacted by shortages (1 patient suffered the lack of appropriate medicine twice).

Proportion of patients impacted by out of supply depending on the type of chemotherapy medicine used



Consequences of out of supply on patients depending on the type of chemotherapy medicine used



Conclusion

- The out of supply of chemotherapy injectable medicine requires for the patient to adapt to the treatment when the treatment should adapt itself to the patient.
- The ruptures lead to loss of chance for patients, even if it can be hard to quantify.
- We can ask the question of a decline in the quality of care of certain cancers in the coming years facing more and more of those regular shortages, and sometimes with no alternative for patients.

